Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 7:23 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,057 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Results available

An Effectiveness-Implementation Trial of SPIRIT in ESRD

NCT03138564
Conditions
End Stage Renal Disease
Interventions
SPIRIT, Comparison Condition
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
39
States / cities
Atlanta, Georgia • Decatur, Georgia • North Decatur, Georgia + 29 more
Completed Phase 3 Interventional Results available

Steroids In Eosinophil Negative Asthma

NCT02066298
Conditions
Asthma
Interventions
Mometasone 220mcg BID, Tiotropium Respimat 5mcg QD, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
25
States / cities
Tucson, Arizona • San Francisco, California • Denver, Colorado + 13 more
Conditions
Gastric Cancer
Interventions
cisplatin, fluorouracil, leucovorin calcium, paclitaxel, surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
30
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 23 more
Completed Not applicable Interventional

Caregiver Bootcamp

NCT07006116
Conditions
Dementia
Interventions
Synchronous/asynchronous online course
Other
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer, Microsatellite Instability-High
Interventions
DPX-Survivac, Cyclophosphamide, Pembrolizumab
Other · Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Boca Raton, Florida + 12 more
Conditions
Bipolar I Disorder, Manic Episode
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more
Conditions
Schizophrenia
Interventions
ALKS 9072, Low dose, ALKS 9072, Med dose, ALKS 9072, High dose, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Atlanta, Georgia • Hoffman Estates, Illinois • St Louis, Missouri + 3 more
Conditions
Kidney Cancer
Interventions
Gemcitabine, Sunitinib
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
99
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Stanford, California + 77 more
Recruiting No phase listed Observational

Nephrotic Syndrome Study Network

NCT01209000
Conditions
Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions
Kidney Biopsy
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Up to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more
Conditions
Spinal Cord Injury
Interventions
Acute Intermittent Hypoxia (AIH), SHAM-Intermittent Room Air
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gefitinib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
95
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
Conditions
Obesity, Overweight, Obstructive Sleep Apnoea
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Gilbert, Arizona • Bradenton, Florida • Naples, Florida + 16 more
Conditions
Hemophilia B, Allergic Reactions
Interventions
Not listed
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
Not listed
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • Atlanta, Georgia + 12 more
Conditions
Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Interventions
ATI-045, Placebo
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
53
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 47 more
Recruiting Not applicable Interventional

Cephea Early Feasibility Study

NCT05061004
Conditions
Mitral Regurgitation
Interventions
Cephea Mitral Valve System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more
Conditions
Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed
Interventions
rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel
Biological
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
36
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

NCT00860067
Conditions
Healthy or Stable Underlying Chronic Medical Condition
Interventions
Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
18
States / cities
Sacramento, California • San Diego, California • San Francisco, California + 15 more
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
102
States / cities
Vestavia Hills, Alabama • Glendale, Arizona • Mesa, Arizona + 90 more
Completed No phase listed Observational Accepts healthy volunteers

BioEnergetics and Metabolomics in Cystic Fibrosis

NCT02225899
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
Interventions
GammaTile
Device
Lead sponsor
GT Medical Technologies, Inc.
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
53
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Castro Valley, California + 45 more
Conditions
Advanced Malignant Solid Neoplasm
Interventions
Adavosertib, Carboplatin, Everolimus, Temozolomide, Trametinib, Veliparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Aurora, Colorado • Atlanta, Georgia • Lexington, Kentucky + 5 more
Conditions
Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Low Dose Radiation Therapy
Other · Radiation
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Familial Adenomatous Polyposis
Interventions
Eflornithine, Eflornithine Placebo, Sulindac 150 MG, Sulindac placebo
Drug
Lead sponsor
Cancer Prevention Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
10
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 7 more
Completed Not applicable Interventional Results available

Effects of Sensory Flicker and Electrical Flicker Stimulation

NCT04188834
Conditions
Brain Diseases
Interventions
Customized version of DAVID device, Blackrock CereStim
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia